指南与共识肥胖与代谢综合征糖尿病

儿童肥胖:评估、治疗与预防——内分泌学会临床实践指南

Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2017-01-01

本指南由内分泌学会工作组采用GRADE方法制定,并委托2项系统综述,聚焦儿童肥胖的评估、治疗与预防。指南指出儿童肥胖影响约17%美国儿童青少年,应分层筛查共病,预防是首要目标;减重药物仅限临床试验,重度青少年可考虑减重手术,需经验丰富团队长期随访。

要点

  • 儿童肥胖影响约17%美国儿童青少年,共病常见,应分层合理筛查。
  • 预防应是首要目标,通过促进健康饮食、活动和环境来实现。
  • 儿童青少年减重药物仅限临床试验;重度成熟青少年可考虑减重手术。

核心结论

  • 儿童肥胖仍是严重的国际健康问题,影响约17%美国儿童青少年,威胁其成年健康与寿命。
  • 儿童肥胖基于遗传易感性,受从宫内到青春期的宽松环境影响;内分泌病因罕见,通常伴生长迟缓。
  • 预防应通过促进健康饮食、活动和环境作为首要目标;肥胖发生后生活方式干预难以取得持久效果。
  • 减重药物在儿童青少年中仅限临床试验;减重手术对生活方式干预失败的最严重成熟青少年显示有效,但需经验丰富团队和长期随访资源。
  • 向成人医疗过渡需连贯规划与持续监测支持,过渡方案尚属未知领域需进一步研究。

研究设计与样本

  • 内分泌学会任命的6名专家工作组、1名方法学家和1名医学撰稿人制定。
  • 采用推荐分级的评估、制定与评价(GRADE)方法描述推荐强度和证据质量。
  • 工作组委托2项系统综述,并使用其他已发表系统综述和个体研究的最佳可得证据。
  • 通过1次小组会议、多次电话会议和电子邮件达成共识;学会委员会、成员和共同主办组织审阅初稿。

主要发现

  • 儿童肥胖影响约17%美国儿童青少年。
  • 内分泌病因罕见,通常伴有生长迟缓模式。
  • 一些行为和药物治疗研究报告了适度成功,但仍需更多可及有效的方法研究。
  • 越来越多的证据表明减重手术对生活方式干预失败的最严重成熟青少年有效。

关键数值与推荐

  • 遗传筛查罕见综合征仅在存在特定病史或体格特征时才有指征。
  • 儿童青少年减重药物使用应限制于临床试验。
  • 减重手术需由经验丰富团队实施,并具备长期随访资源。

临床怎么用

  • 以分层、合理的方式筛查肥胖共病,以便在更严重并发症发生前早期识别。
  • 对个体和家庭的心理负担需筛查心理健康问题并按指征提供咨询。
  • 通过促进健康饮食、活动和环境将儿童肥胖预防作为主要目标。
  • 为接受生活方式治疗、药物方案或减重手术的青少年制定连贯规划,帮助其有效过渡到成人医疗。

局限性

  • 尽管自8年前首次发布指南以来儿童肥胖研究显著增加,仍需进一步研究增加体重风险和影响治疗反应的遗传与生物学因素。
  • 需要更多研究更好地理解导致肥胖个体出现一种共病而非另一种或无共病的遗传与生物学因素。
  • 需要继续研究最有效的预防和治疗肥胖方法,以及改变环境和经济因素以实现全球饮食和活动文化变化的方法。
  • 确定影响食物环境和每日总活动系统性变化的方法以及维持健康体重指数变化的方法尤为重要。
  • 肥胖过渡方案是未知领域,需要进一步研究其有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COSPONSORING ASSOCIATIONS: The European Society of Endocrinology and the Pediatric Endocrine Society. This guideline was funded by the Endocrine Society. OBJECTIVE: To formulate clinical practice guidelines for the assessment, treatment, and prevention of pediatric obesity. PARTICIPANTS: The participants include an Endocrine Society-appointed Task Force of 6 experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The Task Force commissioned 2 systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Endocrine Society committees and members and co-sponsoring organizations reviewed and commented on preliminary drafts of this guideline. CONCLUSION: Pediatric obesity remains an ongoing serious international health concern affecting ∼17% of US children and adolescents, threatening their adult health and longevity. Pediatric obesity has its basis in genetic susceptibilities influenced by a permissive environment starting in utero and extending through childhood and adolescence. Endocrine etiologies for obesity are rare and usually are accompanied by attenuated growth patterns. Pediatric comorbidities are common and long-term health complications often result; screening for comorbidities of obesity should be applied in a hierarchal, logical manner for early identification before more serious complications result. Genetic screening for rare syndromes is indicated only in the presence of specific historical or physical features. The psychological toll of pediatric obesity on the individual and family necessitates screening for mental health issues and counseling as indicated. The prevention of pediatric obesity by promoting healthful diet, activity, and environment should be a primary goal, as achieving effective, long-lasting results with lifestyle modification once obesity occurs is difficult. Although some behavioral and pharmacotherapy studies report modest success, additional research into accessible and effective methods for preventing and treating pediatric obesity is needed. The use of weight loss medications during childhood and adolescence should be restricted to clinical trials. Increasing evidence demonstrates the effectiveness of bariatric surgery in the most seriously affected mature teenagers who have failed lifestyle modification, but the use of surgery requires experienced teams with resources for long-term follow-up. Adolescents undergoing lifestyle therapy, medication regimens, or bariatric surgery for obesity will need cohesive planning to help them effectively transition to adult care, with continued necessary monitoring, support, and intervention. Transition programs for obesity are an uncharted area requiring further research for efficacy. Despite a significant increase in research on pediatric obesity since the initial publication of these guidelines 8 years ago, further study is needed of the genetic and biological factors that increase the risk of weight gain and influence the response to therapeutic interventions. Also needed are more studies to better understand the genetic and biological factors that cause an obese individual to manifest one comorbidity vs another or to be free of comorbidities. Furthermore, continued investigation into the most effective methods of preventing and treating obesity and into methods for changing environmental and economic factors that will lead to worldwide cultural changes in diet and activity should be priorities. Particular attention to determining ways to effect systemic changes in food environments and total daily mobility, as well as methods for sustaining healthy body mass index changes, is of importance.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017. PMID: 28359099. doi:10.1210/jc.2016-2573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。